全文获取类型
收费全文 | 54051篇 |
免费 | 4654篇 |
国内免费 | 951篇 |
专业分类
耳鼻咽喉 | 267篇 |
儿科学 | 2457篇 |
妇产科学 | 866篇 |
基础医学 | 6020篇 |
口腔科学 | 1009篇 |
临床医学 | 6813篇 |
内科学 | 8446篇 |
皮肤病学 | 725篇 |
神经病学 | 930篇 |
特种医学 | 831篇 |
外国民族医学 | 1篇 |
外科学 | 5803篇 |
综合类 | 7913篇 |
现状与发展 | 7篇 |
预防医学 | 10510篇 |
眼科学 | 306篇 |
药学 | 4390篇 |
41篇 | |
中国医学 | 1092篇 |
肿瘤学 | 1229篇 |
出版年
2024年 | 106篇 |
2023年 | 898篇 |
2022年 | 1425篇 |
2021年 | 2529篇 |
2020年 | 2615篇 |
2019年 | 2003篇 |
2018年 | 1961篇 |
2017年 | 1904篇 |
2016年 | 2047篇 |
2015年 | 2248篇 |
2014年 | 3698篇 |
2013年 | 4202篇 |
2012年 | 3686篇 |
2011年 | 3851篇 |
2010年 | 2753篇 |
2009年 | 2527篇 |
2008年 | 2394篇 |
2007年 | 2469篇 |
2006年 | 2368篇 |
2005年 | 2080篇 |
2004年 | 1703篇 |
2003年 | 1496篇 |
2002年 | 1070篇 |
2001年 | 959篇 |
2000年 | 814篇 |
1999年 | 745篇 |
1998年 | 594篇 |
1997年 | 535篇 |
1996年 | 482篇 |
1995年 | 455篇 |
1994年 | 428篇 |
1993年 | 345篇 |
1992年 | 317篇 |
1991年 | 300篇 |
1990年 | 220篇 |
1989年 | 219篇 |
1988年 | 174篇 |
1987年 | 137篇 |
1986年 | 106篇 |
1985年 | 164篇 |
1984年 | 105篇 |
1983年 | 80篇 |
1982年 | 89篇 |
1981年 | 70篇 |
1980年 | 49篇 |
1979年 | 48篇 |
1978年 | 32篇 |
1977年 | 31篇 |
1976年 | 36篇 |
1975年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
21.
目的 分析HBV患者YKL-40、CA19-9、GP73水平差异及与患者病情轻重程度的相关性,探讨HBV患者病情的判定指标。方法 选取2015年5月—2018年5月收治的100例HBV患者,其中慢性HBV感染组40例、慢性乙型肝炎组36例、HBV相关肝硬化组24例,同期选择我院健康体检的健康者50例作为健康对照组;检测患者血中YKL-40、CA19-9、GP73水平;分析HBV感染患者血清YKL-40、CA19-9、GP73水平与病情轻重程度的相关性。结果 慢性HBV感染、慢性乙型肝炎及HBV相关肝硬化患者血中YKL-40水平分别为(36.38±4.19)ng/mL 、(49.02±4.32)ng/mL、(65.14±5.21)ng/mL ,CA19-9分别为(12.03±1.03)KU/L、(13.84±0.98)KU/L、(16.94±0.81)KU/L,GP73分别为(47.22±5.38)ng/mL 、(98.53±10.24)ng/mL 、(229.85±12.19)ng/mL,均明显高于对照组的(28.19±3.27)ng/mL 、(7.34±0.92)KU/L 、(30.93±3.89)ng/mL,均P=0.000 0。随着慢性HBV感染者、慢性乙型肝炎患者和不同HBV相关肝硬化患者肝脏炎症及纤维化程度加重,患者血中YKL-40、CA19-9和GP73也随之显著增加,均P=0.000 0;YKL-40、CA19-9和GP73均是影响HBV感染患者体内炎症坏死及肝脏纤维化的独立性影响因素,差异有统计学意义(P<0.05)。结论 HBV感染患者血清中YKL-40、CA19-9、GP73水平是HBV感染患者病情轻重程度的独立性影响因素。 相似文献
22.
Tuberculosis (TB) remains one of a major health problem worldwide. Tuberculosis vaccine research has made an extraordinary progress over the past few years. However, there is still no replacement for the Bacillus Calmette‐Guérin vaccine, the only TB vaccine licensed for human use. Therefore, the discovery and development of new TB vaccines remains a priority. This article discusses current strategies used to diversify TB vaccines and includes discussion of the status of efforts to improve protection against Mycobacterium tuberculosis (M tb) infection or TB disease by developing new and safe TB vaccines. This article also highlights the current research efforts in immune‐enhancing approaches to improve vaccination efficacy. The development of more effective TB vaccines might have significant impact on global TB control. 相似文献
23.
24.
《Vaccine》2019,37(41):6060-6067
BackgroundVaccination provides protection against infection by inducing VNAs mainly against RABV surface GP. The measurement of VNAs to RABV is commonly used to assess the level of immunity in humans and animals after vaccination. A VNA titer of ≥ 0.5 IU/mL of sera indicates adequate response to vaccination. Here, we report the development and validation of a RABV GP serology ELISA kit for semi-quantitative measurement of VNA titers in sera of vaccinated human subjects.MethodsUsing a recombinant RABV GP expressed in mammalian cells as the capture antigen, the ELISA method was established using HuMAb NM57 reference initially and HRIG reference subsequently. The limit of detection (LOD), linear range, reproducibility, and precision of the method were examined. Specificity and sensitivity were established to assess the diagnostic accuracy.ResultsRABV GP for ELISA plate coating and optimal dilution of human serum sample was 1 µg/mL and 1:20, respectively. Multiple assays were carried out by different technicians at different laboratories for assay standardization. Using the HRIG reference, the LOD was found to be 0.02–0.06 IU/mL and the linear range was 0.2–10.0 IU/ mL. The inter-assay CVs were in the range of 6.60–10.79%, indicating the reproducibility. None of the 12 known negative human sera, tested positive by ELISA, highlighting the specificity. A total of 415 unknown positive human sera were double-blind tested by the RFFIT and ELISA. The VNA titer cut-off value of ELISA was set at 1.5 IU/mL to ensure no false-positive. The diagnostic specificity and sensitivity were 100% and 91.1%, respectively.ConclusionsThe validation data characterize this ELISA as a suitable method for semi-quantitative measurement of VNA titers in human serum samples to assess vaccination status. The ELISA kit can offer simplicity, speed, low cost and high throughput, making it a practical tool for monitoring the immune response following vaccination. 相似文献
25.
关节假体周围感染(periprosthetic joint infection,PJI)是人工关节置换术后可能发生的一种严重并发症,其导致的严重后果,无论对于医生还是患者来说,都很难接受。目前,由于多种不确定因素的存在,PJI诊断的准确性较低。传统的血清学检查、影像学检查有一定的价值,但是易受全身情况的影响,导致特异性不高。为了正确诊断关节假体周围感染,不同学科的研究人员采用各种不同的方法进行了大量的诊断研究,并取得了丰富的成果。近年来,关节滑液炎性标志物检测、分子生物学方法等被研究证实具有较高的敏感性和特异性。因此,关节滑液CRP、-防御素、白细胞酯酶、PCR技术等被广泛研究,期望能从中找到诊断关节假体周围感染的特异性指标,提高临床诊断的准确性。 相似文献
26.
27.
28.
Bacterial keratitis continues to be one of the leading causes of corneal blindness in the developed as well as the developing world, despite swift progress since the dawn of the “anti-biotic era”. Although, we have expeditiously developed our understanding about the different causative organisms and associated pathology leading to keratitis, extensive gaps in knowledge continue to dampen the efforts required for early and accurate diagnosis, and management in these patients, resulting in poor clinical outcomes. The ability of the causative bacteria to subdue the therapeutic challenge stems from their large genome encoding complex regulatory networks, variety of unique virulence factors, and rapid secretion of tissue damaging proteases and toxins.In this review article, we provide an overview of the established diagnostic techniques and therapeutics for keratitis caused by various bacteria. We extensively report the recent in-roads through novel tools for accurately diagnosing mono- and poly-bacterial corneal infections. Furthermore, we outline the recent progress by our groups and others in understanding the sub-cellular genomic changes that lead to antibiotic resistance in these organisms. Finally, we discuss in detail, the novel therapies and drug delivery systems in development for the efficacious management of bacterial keratitis. 相似文献
29.
30.